Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy

Recent advances in familial amyloid polyneuropathy

(2015) Roy Freeman et al.   CURRENT OPINION IN NEUROLOGY

Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance

(2015) Lindsay A. Zilliox et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS©)

(2015) Mariëlle H. J. Pruppers et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Repurposing Diflunisal for Familial Amyloid Polyneuropathy

(2015) John L. Berk et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy

(2014) Etta J. Vinik et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

(2013) D. Binda et al.   EUROPEAN JOURNAL OF CANCER

Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial

(2012) T. Coelho et al.   NEUROLOGY

Development and Psychometric Evaluation of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool

(2011) Cindy S. Tofthagen et al.   CANCER NURSING

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

(2009) Kojiro Shimozuma et al.   SUPPORTIVE CARE IN CANCER